AI Article Synopsis
- Tocilizumab (TCZ) monotherapy has shown effectiveness in treating rheumatoid arthritis (RA), but real-world data in the U.S. is limited.
- The study evaluated the impact of TCZ on disease activity and patient-reported outcomes over one year in patients with RA who had not previously used TCZ.
- Results indicated significant improvements in clinical measures and patient-reported symptoms, regardless of the number of prior TNF inhibitors used, highlighting TCZ's potential in managing RA in everyday clinical settings.
Article Abstract
Introduction: Tocilizumab (TCZ) monotherapy has been proven as an effective treatment for rheumatoid arthritis (RA) in clinical trials. However, there are limited data available regarding the effectiveness of TCZ monotherapy in real-world clinical settings in the United States. The objective of this study was to evaluate the impact of TCZ monotherapy on disease activity and patient-reported outcomes (PROs) in a US-based observational cohort of patients with RA seen in routine clinical practice.
Methods: Eligible patients had active RA, no prior use of TCZ, and initiated TCZ as monotherapy. Changes in disease activity and PROs were assessed 1 year after TCZ initiation for the overall cohort and stratified by number of prior tumor necrosis factor inhibitors (TNFis; 0, 1, or ≥2). Primary outcomes were change in Clinical Disease Activity Index (CDAI); change in patient global disease activity, pain, fatigue; and the proportions of patients with improvement in modified Health Assessment Questionnaire (mHAQ), morning stiffness, and EQ-5D.
Results: Of 255 eligible TCZ monotherapy initiators, 9.4% were TNFi naive, 36.5% had one prior TNFi, and 54.1% had ≥2 prior TNFis. Clinical and PRO measures indicated that patients were substantially impacted by their disease at baseline. The median decrease in CDAI from baseline to 1 year was 9.8 and median patient global and pain scores improved by 10 mm, indicative of clinically meaningful improvement; the median fatigue score improved by 5 mm. Approximately 26% of patients reported clinically meaningful improvement in mHAQ, 54% experienced improvement in morning stiffness, and 20% to 36% experienced improvement in EQ-5D domains (walking, self-care, usual activities, pain/discomfort, and anxiety/depression). Improvements were similar across TNFi groups.
Conclusions: Patients with active, refractory RA who initiated TCZ monotherapy experienced improvements in both composite disease activity scores and PROs at 1 year, regardless of prior TNFi exposure.
Funding: Corrona, LLC and Genentech.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5696293 | PMC |
| http://dx.doi.org/10.1007/s40744-017-0081-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy and safety of tocilizumab treatment in refractory MOG-IgG related optic neuritis.
Ther Adv Neurol Disord
December 2024
Department of Ophthalmology, The Third Medical Center of Chinese PLA General Hospital, No. 28 Fuxing Road, Beijing 100853, China.
Background: Myelin oligodendrocyte glycoprotein (MOG) IgG related optic neuritis (ON) which manifests as recurrent episodes and severe visual impairment remains a challenging issue in relapse prevention. Tocilizumab (TCZ), a human monoclonal antibody against IL-6R, may be an alternative treatment for the prevention of relapse in refractory MOG-ON patients.
Objectives: To investigate the efficacy and safety of Tocilizumab (TCZ) in patients with recurrent myelin oligodendrocyte glycoprotein IgG related optic neuritis (MOG-ON).
Interleukin 41 As A Potential Predictor of Bio-Therapy Efficacy In Patients With Rheumatoid Arthritis: A Prospective Observational Study.
Int J Med Sci
October 2024
Faculty of Medical Sciences, Center for Molecular Medicine and Stem Cell Research, University of Kragujevac, Kragujevac, Serbia.
Article Synopsis
- A new cytokine called IL-41 is linked to several autoimmune diseases, including rheumatoid arthritis (RA), and this study seeks to evaluate its potential as a biomarker for RA treatment effectiveness and patient responses.
- The research involves 189 patients from a Serbian rheumatology clinic, split into groups based on their treatment: methotrexate alone, methotrexate with TNF inhibitors, or the IL-6 inhibitor tocilizumab.
- Results show that tocilizumab significantly lowers IL-41 levels and improves disease symptoms the most, while smoking is identified as a major predictor of higher IL-41 concentrations in RA patients.
Treatment of giant cell arteritis with ultra-short glucocorticoids and tocilizumab: results from the extension of the TOPAZIO study.
Rheumatology (Oxford)
August 2024
Rheumatology Unit, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
Objectives: To assess the maintenance of efficacy of one year of tocilizumab (TCZ) monotherapy after its discontinuation in large vessel-GCA (LV-GCA).
Methods: 17 patients with active LV-GCA were previously treated with 3 boluses of intravenous methylprednisone and weekly subcutaneous TCZ in monotherapy for 52 weeks. Patients in relapse-free clinical remission at week 52 discontinued TCZ and entered part two, which was a 26-week observational follow-up period.
Tocilizumab use in giant cell arteritis: comparing Pharmaceutical Benefits Scheme eligible and ineligible cases in South Australia.
Intern Med J
July 2024
Rheumatology Unit, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
Tocilizumab (TCZ) is increasingly used as a steroid-sparing agent in giant cell arteritis (GCA), but there are strict Pharmaceutical Benefits Scheme (PBS) restrictions for its use in Australia. Patients who do not meet the PBS criteria can obtain TCZ through public hospital individual patient use (IPU) schemes which may not be universally accessible. We compared patients receiving IPU-approved TCZ with patients receiving PBS-subsidised TCZ and found IPU approvals were granted mainly for visual loss, a serious complication of GCA, in patients who otherwise failed to meet PBS criteria.
View Article and Find Full Text PDFOutcomes of Intravenous Tocilizumab Treatment for Refractory Pars Planitis.
Ocul Immunol Inflamm
May 2024
Ophthalmology, Massachusetts Eye Research and Surgery Institution, Waltham, Massachusetts, USA.
Purpose: To evaluate outcomes of intravenous (IV) tocilizumab (TCZ) in patients with pars planitis refractory to conventional immunomodulatory therapy and anti-tumor necrosis factor (TNF) alpha agents.
Methods: Medical records of eight patients diagnosed with pars planitis and treated with monthly 4 or 8 mg/kg IV TCZ were reviewed. The primary objective was to initiate and sustain remission continuously for three consecutive months.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!